COVID-19, a new pandemic, has entered the scene dominating news cycles and causing real death and destruction on a global scale. Our health care workers are overwhelmed, and many are falling ill themselves. The FDA has allowed for clinical trials of convalescent plasma donations to help save the critically ill, and news outlets are reporting that some experts wonder if it could temporarily immunize front-line workers.
FDA requirements for treating patients are specific for both donor and recipient, and test results for original COVID-19 diagnosis and subsequent negative test results are required, among other factors. Donors must also first be eligible to donate blood to participate, which has its prerequisites.
Tests for COVID-19 are plentiful in some places and scarce in others. This obscures badly needed data to fight a pandemic, especially one in which survivors can potentially save those still fighting it.
In the U.S., states have different definitions, and restrictions for ‘social distancing,’ choosing how much or little its citizens can venture out. Testing resources and travel restrictions vary in other countries as well. It is highly likely that we will see COVID-19 re-emerge later due to different attitudes and leadership decisions of -nations and states- around the world.
While this disease spreads easily airborne from person to person, it respects no geographical boundaries. The tools and resources, especially the data needed to glean the feasibility of convalescent plasma treatment in the case of COVID-19, must be prolific and global as well.
While convalescent plasma treatments aren’t new, this Novel Coronavirus is. In these desperate times, the FDA has paved the way for clinical trials to gauge the treatment’s efficacy. It is now up to front-line healthcare professionals to apply to the FDA to implement it in specific cases in such a fashion that maximum data can be amassed and analyzed. The requirements above and tests for potential COVID-19 plasma donors should be a minimum.
Further data about the donor’s presentation of symptoms, length of disease, and underlying conditions should be recorded to learn what kinds of donors are best suited for this program. Data about the time of treatment and stage of symptoms must be registered. It might be prudent to track the donor, as it is unknown whether someone who has previously had COVID-19 might contract it again. That data should reside at a third-party, HIPAA-compliant data company so that it may be anonymized and shared when requested by stakeholders.
Another challenge for convalescent plasma treatment for COVID-19 is logistics. In the U.S., not everyone who has recovered from COVID-19 has proof that they ever had it. This possibility, coupled with prerequisite blood donor requirements, could lead to a supply issue for antibody-rich plasma reaching those who need it, especially once approved for the general public.
There is also an issue of communicating eligibility information to qualifying plasma donors and in motivating said individuals to donate. Even though one plasma donor could save up to five people, COVID-19 plasma may have to come from another state or country to fulfill the need, if approved.
SignaKey, LLC, and SAHAVE are working together to aid in the fight against this pandemic to facilitate a global data, supply chain, and marketing solution for COVID-19 convalescent plasma. SignaKey is an IEC Global Standard technology used for authentication, serialization, supply chain integrity, and tracking of products. SignaKey’s are 2-D, unambiguously unique marks that can hold unlimited information about the product it identifies.
SignaKeys can link to test results and all prerequisite information about the donor, the date, time and location of the donation, the plasma donation center, medical employee ID, and any other data properties deemed worthy of record. Access is by scanning a sticker on the plasma bag or receptacle with an app on one’s smartphone.
The decoded information is scalable. Varying layers of data can be accessible by authorized parties. Each scan or decode creates a stable block of data about the product. Decoding captures the user, date, time, and geospatial coordinates. Scanning SignaKeys into and out of custody at each step of the process captures it all.
SignaKey is a private domain technology and cannot be reproduced, unlike barcodes or QR codes, which are in the public domain. SignaKey has marketing capabilities as well. The plasma donor can scan them at the time of donation, and when it is scanned again for transfusion to a patient; the donor may receive the message that their donation ‘saved a life today.’
SAHAVE is the pioneer of the nonprofit world, building trust and connection between people, nonprofit organizations, and businesses.
Our mission is to inspire social change by motivating donors to help one another while benefiting themselves and their communities; to provide support to nonprofit organizations to increase their overall impact and effectiveness; and to create safe, effective, and efficient solutions for life-saving blood delivery.
In the SAHAVE world, nonprofits can easily reach out directly to individuals in targeted geographic areas, who are ready and willing to help, when it is needed most.
In general, people are good-at-heart and want to help others. But we, as humans, also value convenience. SAHAVE maximizes the human capital potential by conveniently getting the call-for-help out to service-hearted individuals when they are most willing to take action, and their help is most needed.
For Hospitals and Blood Centers, SAHAVE provides on-demand blood donations matched to eligible donors, pre-donation screening, and revolutionizes the blood supply chain.
Currently, We are saving lives in India by partnering with the Indian Red Cross and over 70 nonprofits and blood centers to encourage blood donations while streamlining the efficiency of their use in the face of critical blood shortages and a black-market blood mafia. We have over 250,000 donors in our database, 100+ people on our platform, and a short-term goal to attract 100,000 new blood donors in 100 days. With advanced technology, we can dramatically improve the efficiency of the blood supply chain, eventually providing safe, screened blood on demand.
We are launching our movement in the United States for COVID plasma delivery.